Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1805 - PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer


09 Sep 2017


Poster display session


Yukiya Narita


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


Y. Narita1, E. Sasaki2, Y. Yatabe2, K. Kato1, H. Okano1, S. Mitani1, K. Honda1, T. Masuishi1, H. Taniguchi1, S. Kadowaki1, T. Ura1, M. Ando1, M. Tajika3, S. Ito4, K. Muro1

Author affiliations

  • 1 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Department Of Pathology And Molecular Diagnostics, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 3 Department Of Endoscopy, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Department Of Gastroenterological Surgery, Aichi Cancer Center Hospital, 4648681 - Nagoya/JP


Abstract 1805


Recent genomic and molecular characterization of gastric adenocarcinoma (GAC), such as Cancer Genome Atlas (TCGA), have shed light on the PD-L1 positivity and four different subtypes. Several PD-L1 IHC assays of scoring-criteria are developed in parallel. This study aimed to evaluate PD-L1 staining patterns and molecular profiling by TMA in GAC.


In total, 331 consecutive patients (pts) with GAC underwent curative surgery at Aichi Cancer Center Hospital between Jan 2009 and Dec 2010. Pts with no systemic chemotherapy before surgery and sufficient tumor content on the formalin-fixed and paraffin-embedded (FFPE) slides were eligible. EBV-encoded RNA in situ hybridization, IHC for deficient mismatch repair proteins (dMMR, MLH1/MSH2/MSH6/PMS2), HER2 and PD-L1 (22C3, 28-8, E1L3), and HER2 DISH were evaluated in TMA. Four cores of tumor tissue were punched out from individual FFPE tumor blocks and arrayed in a new TMA block. PD-L1 tumor positivity was categorized to ≥ 1%/≥25%/≥50% tumor cell membrane staining. Disease free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method.


Among the cases, 226 pts were included in this study, excluding pts with prior chemotherapy (n = 26) and insufficient tumor samples (n = 79). Patient characteristics were as follows: male/female, 162/64; pStage (AJCC 7th ed.) I/II/III/IV, 100/39/58/29; EBV +/-, 13/213; proficient MMR/dMMR, 197/29, HER2 +/-, 24/202, and PD-L1 ≥1%/≥25%/≥50% (22C3 vs. 28-8 vs. E1L3), 11/4/2 vs. 7/6/6 vs. 12/10/8. Among 22C3, 28-8, and E1L3 assays, 94–97% of the pairs were concordant. PD-L1 positivity by all three assays was associated with EBV + (p 


The three tested PD-L1 assays did not show comparable staining patterns in all cases. Studies that correlate not only PD-L1 staining patterns but also EBV+/dMMR/HER2+ and response to immunotherapy are required to evaluate.Table:


EBV+ N = 13EBV− N = 213PpMMR N = 197dMMR N = 29PHER2+ N = 24HER2− N = 202P
E1L3+ −3 109 2040.028 1914 250.060 2412 1900.62
28-8+ −3 104 209

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.